As 2025 comes to a close, we reflect on a defining year for nymble - bringing accessible behavioural support to thousands across three countries, launching core platform capabilities, and grounding our mission in a simple truth: real-world healthcare impact requires simplicity, trust, and meeting people where they are.

The WHO has released its first global guideline on GLP-1 therapies for obesity — finally treating obesity as a chronic disease requiring long-term, integrated care. It marks a pivotal shift: medications are necessary but not enough, behavioural support must be sustained, and real-world data will shape the future of obesity care globally.

Awareness of GLP-1 medications is rising online, but it’s far from universal. In many countries, most people don’t even know these treatments exist—making care feel out of reach. nymble closes that gap with clear, clinically grounded support delivered through SMS and WhatsApp, in people’s own language. No apps, no barriers—just trustworthy guidance that meets people where they are.